Hearing loss prevention pill put to the test — but study never started
NCT ID NCT02779192
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to test whether an oral drug called SPI-1005 (ebselen) could prevent temporary hearing loss caused by loud noise. Researchers planned to enroll adults aged 18-50 with a history of noise exposure and give them the drug or a placebo for 7 days, then measure hearing changes after a controlled sound challenge. However, the trial was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPI-1005 (ebselen)
What this could lead to
If it works, this could point toward a pill that protects against hearing loss from loud noise.
What could go wrong
The study was withdrawn before enrolling anyone, so no results exist. It is unclear if the drug is effective or safe for this use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOISE INDUCED HEARING LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MUSC
Charleston, South Carolina, 29425, United States
-
Sound Pharmaceuticals, Inc.
Seattle, Washington, 98103, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66103, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States